Is DWTX or PALI more profitable?

Palisade Bio's return on equity of -33.47% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -75.55% -40.28% Palisade Bio N/A -33.47% -31.79%

Does the media favor DWTX or PALI?

In the previous week, Palisade Bio had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Palisade Bio and 3 mentions for Dogwood Therapeutics. Palisade Bio's average media sentiment score of 1.77 beat Dogwood Therapeutics' score of 0.96 indicating that Palisade Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is IKT or DWTX more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% Dogwood Therapeutics N/A -75.55% -40.28%

Does the media refer more to IKT or DWTX?

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 3 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.89 beat Dogwood Therapeutics' score of 0.96 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dogwood Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DWTX or VNDA?

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Vanda Pharmaceuticals and 3 mentions for Dogwood Therapeutics. Vanda Pharmaceuticals' average media sentiment score of 1.34 beat Dogwood Therapeutics' score of 0.96 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DWTX or AMRN?

In the previous week, Amarin had 4 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 7 mentions for Amarin and 3 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.96 beat Amarin's score of 0.91 indicating that Dogwood Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, TTRX or DWTX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A Dogwood Therapeutics N/A N/A -$34.26M -$8.95 N/A

Is TTRX or DWTX more profitable?

Dogwood Therapeutics' return on equity of -75.55% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A -230.84% -53.19% Dogwood Therapeutics N/A -75.55% -40.28%

Does the media refer more to TTRX or DWTX?

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 1.83 beat Dogwood Therapeutics' score of 0.96 indicating that Turn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dogwood Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dogwood Therapeutics (DWTX) Competitors

$2.63 +0.05 (+1.94%)

As of 04:00 PM Eastern

Compare

DWTX vs. PALI, IKT, VNDA, AMRN, and TTRX

Should you buy Dogwood Therapeutics stock or one of its competitors? Dogwood Therapeutics's main competitors and comparable companies include Palisade Bio (PALI), Inhibikase Therapeutics (IKT), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), and Turn Therapeutics (TTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dogwood Therapeutics compare to Palisade Bio?

Dogwood Therapeutics (NASDAQ:DWTX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Dogwood Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 356.27%. Palisade Bio has a consensus price target of $9.00, suggesting a potential upside of 359.18%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Dogwood Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Palisade Bio's return on equity of -33.47% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Palisade Bio	N/A	-33.47%	-31.79%

In the previous week, Palisade Bio had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Palisade Bio and 3 mentions for Dogwood Therapeutics. Palisade Bio's average media sentiment score of 1.77 beat Dogwood Therapeutics' score of 0.96 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Palisade Bio has higher revenue and earnings than Dogwood Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Palisade Bio	$250K	1,366.28	-$16.78M	-$0.48	N/A

Summary

Palisade Bio beats Dogwood Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Inhibikase Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 3 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.89 beat Dogwood Therapeutics' score of 0.96 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Dogwood Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dogwood Therapeutics has lower revenue, but higher earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,277.33	-$48.26M	-$0.43	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

Inhibikase Therapeutics' return on equity of -42.80% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Dogwood Therapeutics	N/A	-75.55%	-40.28%

Inhibikase Therapeutics currently has a consensus target price of $5.40, suggesting a potential upside of 126.89%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 356.27%. Given Dogwood Therapeutics' higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Inhibikase Therapeutics beats Dogwood Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Vanda Pharmaceuticals?

Dogwood Therapeutics (NASDAQ:DWTX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Dogwood Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 356.27%. Vanda Pharmaceuticals has a consensus target price of $13.70, suggesting a potential upside of 152.77%. Given Dogwood Therapeutics' higher possible upside, equities analysts plainly believe Dogwood Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dogwood Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Vanda Pharmaceuticals and 3 mentions for Dogwood Therapeutics. Vanda Pharmaceuticals' average media sentiment score of 1.34 beat Dogwood Therapeutics' score of 0.96 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dogwood Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

Dogwood Therapeutics has higher earnings, but lower revenue than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Vanda Pharmaceuticals	$216.10M	1.52	-$220.47M	-$4.63	N/A

Summary

Vanda Pharmaceuticals beats Dogwood Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Amarin?

Dogwood Therapeutics (NASDAQ:DWTX) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 4.2% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dogwood Therapeutics has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Amarin	$213.65M	1.37	-$38.80M	-$0.99	N/A

In the previous week, Amarin had 4 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 7 mentions for Amarin and 3 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.96 beat Amarin's score of 0.91 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dogwood Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Amarin has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 356.27%. Amarin has a consensus price target of $13.00, suggesting a potential downside of 6.14%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Dogwood Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Amarin	-14.56%	-0.20%	-0.14%

Summary

Dogwood Therapeutics beats Amarin on 8 of the 15 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Turn Therapeutics presently has a consensus target price of $8.00, indicating a potential downside of 18.53%. Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 356.27%. Given Dogwood Therapeutics' higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 1.83 beat Dogwood Therapeutics' score of 0.96 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Dogwood Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

9.1% of Dogwood Therapeutics shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dogwood Therapeutics' return on equity of -75.55% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Dogwood Therapeutics	N/A	-75.55%	-40.28%

Summary

Dogwood Therapeutics beats Turn Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Dogwood Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DWTX vs. The Competition

Export

Metric	Dogwood Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$89.39M	$12.09B	$7.13B	$12.68B
Dividend Yield	N/A	2.62%	2.54%	10.96%
P/E Ratio	-0.29	785.16	272.60	25.07
Price / Sales	N/A	760.09	618.63	97.84
Price / Cash	N/A	15.32	28.78	36.03
Price / Book	1.13	10.52	11.06	6.25
Net Income	-$34.26M	$2.82B	$3.47B	$348.99M
7 Day Performance	-1.87%	1.84%	-0.80%	-2.37%
1 Month Performance	60.37%	4.74%	7.16%	2.98%
1 Year Performance	-46.98%	9.06%	24.67%	13.69%

Dogwood Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DWTX Dogwood Therapeutics	2.4246 of 5 stars	$2.63 +1.9%	$12.00 +356.3%	-48.0%	$89.39M	N/A	N/A	5	Short Interest Decrease Gap Up
PALI Palisade Bio	2.7857 of 5 stars	$2.07 -0.2%	$9.00 +335.8%	+188.5%	$358.13M	$250K	N/A	10
IKT Inhibikase Therapeutics	2.3208 of 5 stars	$2.48 -0.8%	$5.40 +117.7%	N/A	$345.36M	$260K	N/A	6	News Coverage
VNDA Vanda Pharmaceuticals	2.9065 of 5 stars	$5.40 -0.7%	$13.70 +153.6%	+14.2%	$323.40M	$216.10M	N/A	290	Positive News
AMRN Amarin	0.9448 of 5 stars	$15.22 +7.5%	$13.00 -14.6%	-7.7%	$312.66M	$213.65M	N/A	360	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DWTX) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. PALI, IKT, VNDA, AMRN, and TTRX

How does Dogwood Therapeutics compare to Palisade Bio?

Summary

How does Dogwood Therapeutics compare to Inhibikase Therapeutics?

Summary

How does Dogwood Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Dogwood Therapeutics compare to Amarin?

Summary

How does Dogwood Therapeutics compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. PALI, IKT, VNDA, AMRN, and TTRX

How does Dogwood Therapeutics compare to Palisade Bio?

Which has more volatility & risk, DWTX or PALI?

Do insiders and institutionals hold more shares of DWTX or PALI?

Do analysts recommend DWTX or PALI?

Is DWTX or PALI more profitable?

Does the media favor DWTX or PALI?

Which has better valuation and earnings, DWTX or PALI?

Summary

How does Dogwood Therapeutics compare to Inhibikase Therapeutics?

Which has more volatility and risk, IKT or DWTX?

Does the media refer more to IKT or DWTX?

Which has higher valuation & earnings, IKT or DWTX?

Is IKT or DWTX more profitable?

Do analysts rate IKT or DWTX?

Do insiders and institutionals hold more shares of IKT or DWTX?

Summary

How does Dogwood Therapeutics compare to Vanda Pharmaceuticals?

Do analysts rate DWTX or VNDA?

Which has more risk & volatility, DWTX or VNDA?

Do institutionals & insiders hold more shares of DWTX or VNDA?

Does the media prefer DWTX or VNDA?

Is DWTX or VNDA more profitable?

Which has higher earnings & valuation, DWTX or VNDA?

Summary

How does Dogwood Therapeutics compare to Amarin?

Do insiders & institutionals hold more shares of DWTX or AMRN?

Which has preferable earnings and valuation, DWTX or AMRN?

Does the media prefer DWTX or AMRN?

Which has more risk & volatility, DWTX or AMRN?

Do analysts recommend DWTX or AMRN?

Is DWTX or AMRN more profitable?

Summary

How does Dogwood Therapeutics compare to Turn Therapeutics?

Do analysts rate TTRX or DWTX?

Does the media refer more to TTRX or DWTX?

Which has preferable valuation and earnings, TTRX or DWTX?

Do insiders & institutionals believe in TTRX or DWTX?

Is TTRX or DWTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools